Spurned J&J vice chair jumps ship for Avon; Roche may boost Illumina bid again;

 @FierceMedDev: FDA approves Lilly's brain plaque diagnostic tool. Item | Follow @FierceMedDev

> Johnson & Johnson ($JNJ) Vice Chairman Sherilyn S. McCoy will leave the company to become CEO of Avon Products, two months after being passed over for J&J's top spot in favor of Alex Gorsky, The Wall Street Journal reports. Blog

> BioMarCare Technologies plans to use a $900,000 grant from the Israel-United States Binational Industrial Research and Development Foundation to develop biomarkers that help predict the response to certain drugs for colon cancer patients, Globes reports. Story

> On-Q-ity is generating promising data for OnQChip, a technology designed to detect circulating tumor cells in the blood of cancer patients. The company presented details at the recent AACR meeting in Chicago. Release

> California's Bioness has begun a clinical study to evaluate the safety and effectiveness of its StimRouter neuromodulation system to treat chronic peripheral nerve pain. Release

> Mount Sinai School of Medicine researchers have developed a way to derive enough DNA information from non-DNA sources--such as RNA--to clearly identify patients whose biological data is stored in massive research repositories. Release

And Finally... Roche ($RHHBY) has said it is willing to consider "additional value" in its ongoing bid for Illumina ($ILMN), suggesting that it may raise its offer for the company again, Reuters reports. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.